INCY — INCYTE CORP

—
Nasdaq · Health Care · Life Sciences Tools & Services · CIK 879169 ·
Last close
$119.09
Market Cap
$24.27B
52W High
$132.60
52W Low
$89.25
ADV30
1,754,132
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,557,204,000 1,448,504,000 -707,452,000 -784,803,000 7,287,257,000 3,275,881,000 1,644,320,000
Jun 2026 1,674,039,000 1,569,039,000 700,389,000 585,605,000 7,872,647,000 3,982,375,000 1,528,220,000
Mar 2026 1,272,676,000 1,168,176,000 324,173,000 303,330,000 7,339,113,000 3,461,114,000 1,716,266,000
Dec 2025 1,506,835,000 1,385,735,000 383,963,000 299,279,000 6,957,973,000 3,097,817,000 1,790,495,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$744,992,000
Investing CF
$-221,750,000
Financing CF
$301,955,000
CapEx
$-65,121,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$1.88
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$317,901,000
Inventory
$134,252,000
Receivables
$1,237,027,000
ST Investments
$578,691,000
EBIT TTM
$798,545,000
Pretax Income TTM
$796,207,000
Interest Exp TTM
$2,338,000
Analysts
24

Yahoo Snapshot (yfinance, live)

Total Revenue
$6,010,754,048
EBITDA
$2,035,372,032
Free Cash Flow
$1,286,754,432
Enterprise Value
$20,722,233,344
Total Cash
$3,854,572,032
Total Debt
$37,412,000
Shares Out
203,832,492
Trailing EPS
$1.96
Book Value
$27.66
ROE
7.8%
ROA
17.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 5,141,242,000 1,342,790,000 1,286,650,000 6,957,973,000 1,790,495,000 5,167,478,000 1,413,498,000
Dec 2024 4,241,217,000 101,294,000 32,615,000 5,444,322,000 1,996,694,000 3,447,628,000 335,337,000
Dec 2023 3,695,649,000 655,358,000 597,599,000 6,782,107,000 1,592,270,000 5,189,837,000 496,487,000
Dec 2022 3,394,635,000 591,626,000 340,660,000 5,840,984,000 1,470,865,000 4,370,119,000 969,941,000

TTM Snapshot

Revenues TTM
$5,819,530,000
NetIncome TTM
$1,612,383,000
OpCashFlow TTM
—
Assets (Latest)
$7,872,647,000
Forward EPS
$8.73

Max Pain — expiry 2026-12-18

max pain strike: $120.00 · spot: $117.80 · call oi: 4,604 · put oi: 12,517
Expected Move to 2026-12-18: ±$13.65 (11.59%) — implied range $104.15 – $131.45 · ATM straddle on $120.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MEDP Medpace Holdings, Inc. $18.27B $653.09 —
CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC. $15.92B $332.16 —
ICLR ICON PLC $15.05B $195.02 —
IQV IQVIA HOLDINGS INC. $42.45B $257.60 —
IDXX IDEXX LABORATORIES INC /DE $54.38B $690.24 —

News headlines (Yahoo Finance, 1h cache)

Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa
2026-11-16 21:30 · Yahoo
How Incyte Trial And New Cancer Data Will Impact Natera Stock
2026-11-13 05:13 · Yahoo
Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030
2026-11-11 13:12 · Yahoo
Natera and Incyte partner on Phase II colorectal cancer trial
2026-11-11 11:19 · Yahoo
Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
2026-11-10 12:00 · Yahoo
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026
2026-11-04 14:00 · Yahoo
Incyte to Present at Upcoming Investor Conferences
2026-11-04 13:00 · Yahoo
What Does Incyte (INCY) First Patient Dosing Mean For Its Colorectal Cancer Pipeline?
2026-10-31 22:09 · Yahoo
Incyte (INCY) Q3 2026 Earnings Call Transcript
2026-10-29 22:45 · Yahoo
Natera (NTRA) Following Clinical Momentum Looks Fully Valued To Some
2026-11-13 04:36 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.